Company Page
HexemBio
HexemBio is a longevity biotech company pioneering the world's first blood stem cell rejuvenation therapy. Built around the Synthetic Human Yolk Sac platform, the technology recreates the embryonic microenvironment where blood stem cells first form, temporarily placing a patient's own aged hematopoietic stem cells into this environment to restore youthful function before returning them via standard IV infusion. The company's lead clinical program targets bone marrow transplant outcomes in blood cancer patients, including acute myeloid leukemia and acute lymphoblastic leukemia. HexemBio has received FDA Orphan Drug Designation, completed its FDA Pre-IND meeting in January 2026, and is targeting first-in-human trials in 2027. Its foundational science was published in Nature and featured in the New York Times, and the platform is protected by 15+ USPTO-filed patents.
Company Founded in 2024
Healthtech & Biotech